Clinical Trial Search

Primary: Change in Severity of Lesions(Degree of Reticular, Erythematous and Ulceration) by Using Piboonniyom REU Severity Score — 2.15; 0.73 Scores on a scale — p=0.004

Primary: Cmax for Serum Deferiprone — 3.89; 2.76; 3.02; 13.89 μg/mL

Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 29; 5 participants

Primary: Percentage of Participants Achieving Pathological Complete Response (pCR) — 29.0; 45.8; 16.8; 24.0 percentage of participants — p=0.0094

Primary: Number of Participants With the Indicated Percent Reduction From Baseline in Oral Corticosteroid (OCS) Dose During Weeks 20 to 24 While Maintaining Asthma Control — 7…

Primary: Number of Participants With Treatment-emergent Non-Serious Adverse Events (AEs) and Treatment-emergent Serious Adverse Events (SAEs) — 1018; 288 participants

Primary: Migraine Frequency: Change From Baseline 12-week Period to Weeks 1 to 12 — -8.0; 1.0 days

Primary: Number of Participants With Non-Serious Adverse Events (AEs) and Serious Adverse Events (SAEs) — 132; 11 Participants

Primary: Number of Clinically Significant Exacerbations of Asthma Per Year — 1.74; 0.93; 0.83 Number of exacerbations per year — p=<0.001

Primary: Objective Response Rate — 56.47; 37.93 percentage of participants

Primary: Physical Violence From School Staff — 595; 924 participants — p=<0.0001

Primary: Number of Female Subjects With Overall Vaccine Effectiveness Against Genital Infection With Human Papilloma Virus (HPV)-16/18 Types in Cervarix/Engerix-B B Group Versus…

Primary: Percentage of Participants With Mean Corrected Total Serum Calcium Concentration ≤ 10.3 mg/dL (2.57 mmol/L) During the EAP — 0.0; 75.8 percentage of participants…

Primary: The Primary Goal of This Study is to Show That the Addition of Bevacizumab to Cisplatin-based Chemotherapy in the Neoadjuvant Setting for Non-squamous Cell Carcinomas…

Primary: Objective Response Rate (Complete and Partial Response) — 26.7; 9.1 percentage of participants